Invivyd, Inc. (IVVD)
IVVD Stock Price Chart
Explore Invivyd, Inc. interactive price chart. Choose custom timeframes to analyze IVVD price movements and trends.
IVVD Company Profile
Discover essential business fundamentals and corporate details for Invivyd, Inc. (IVVD) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
6 Aug 2021
Employees
99.00
Website
https://adagiotx.comCEO
William E. Duke Jr.,
Description
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
IVVD Financial Timeline
Browse a chronological timeline of Invivyd, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 18 Mar 2026
Upcoming earnings on 13 Nov 2025
EPS estimate is -$0.01, while revenue estimate is $12.00M.
Earnings released on 14 Aug 2025
EPS came in at -$0.12 falling short of the estimated -$0.04 by -200.00%, while revenue for the quarter reached $11.79M , missing expectations by -59.37%.
Earnings released on 15 May 2025
EPS came in at -$0.14 falling short of the estimated -$0.04 by -250.00%, while revenue for the quarter reached $11.30M , missing expectations by -35.41%.
Earnings released on 20 Mar 2025
EPS came in at -$0.15 surpassing the estimated -$0.25 by +40.00%, while revenue for the quarter reached $13.82M , missing expectations by -59.88%.
Earnings released on 14 Nov 2024
EPS came in at -$0.51 falling short of the estimated -$0.33 by -54.55%, while revenue for the quarter reached $9.30M , missing expectations by -32.93%.
Earnings released on 14 Aug 2024
EPS came in at -$0.40 falling short of the estimated -$0.37 by -8.11%, while revenue for the quarter reached $2.26M , missing expectations by -54.72%.
Earnings released on 9 May 2024
EPS came in at -$0.38 surpassing the estimated -$0.51 by +25.49%.
Earnings released on 28 Mar 2024
EPS came in at -$0.67 falling short of the estimated -$0.41 by -63.41%, while revenue for the quarter reached $3.02M .
Earnings released on 9 Nov 2023
EPS came in at -$0.36 surpassing the estimated -$0.54 by +33.33%.
Earnings released on 10 Aug 2023
EPS came in at -$0.46 falling short of the estimated -$0.40 by -15.00%.
Earnings released on 11 May 2023
EPS came in at -$0.32 surpassing the estimated -$0.36 by +11.11%.
Earnings released on 23 Mar 2023
EPS came in at -$0.41 falling short of the estimated -$0.39 by -5.13%.
Earnings released on 10 Nov 2022
EPS came in at -$0.42 surpassing the estimated -$0.46 by +8.70%.
Earnings released on 15 Aug 2022
EPS came in at -$0.47 surpassing the estimated -$0.57 by +17.54%.
Earnings released on 13 May 2022
EPS came in at -$0.93 falling short of the estimated -$0.82 by -13.41%.
Earnings released on 30 Mar 2022
EPS came in at -$0.77 surpassing the estimated -$1.03 by +25.24%.
Earnings released on 15 Nov 2021
EPS came in at -$0.98 falling short of the estimated -$0.74 by -32.43%, while revenue for the quarter reached $3.00 , beating expectations by +33.33%.
Earnings released on 20 Sept 2021
EPS came in at -$0.18 surpassing the estimated -$0.80 by +77.50%.
Earnings released on 6 Aug 2021
EPS came in at -$0.61 .
Earnings released on 31 Dec 2020
EPS came in at -$11.42 .
Earnings released on 30 Sept 2020
EPS came in at -$0.76 .
IVVD Stock Performance
Access detailed IVVD performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.